ATE132195T1 - Rekombinant-mykobakterielle impfstoffe - Google Patents

Rekombinant-mykobakterielle impfstoffe

Info

Publication number
ATE132195T1
ATE132195T1 AT88903026T AT88903026T ATE132195T1 AT E132195 T1 ATE132195 T1 AT E132195T1 AT 88903026 T AT88903026 T AT 88903026T AT 88903026 T AT88903026 T AT 88903026T AT E132195 T1 ATE132195 T1 AT E132195T1
Authority
AT
Austria
Prior art keywords
replicates
useful
recombinant mycobacterial
shuttle vector
vaccine vehicles
Prior art date
Application number
AT88903026T
Other languages
English (en)
Inventor
Barry R Bloom
Ronald W Davis
William R Jacobs Jr
Richard A Young
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE132195T1 publication Critical patent/ATE132195T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/32—Mycobacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT88903026T 1987-03-02 1988-02-29 Rekombinant-mykobakterielle impfstoffe ATE132195T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2045187A 1987-03-02 1987-03-02

Publications (1)

Publication Number Publication Date
ATE132195T1 true ATE132195T1 (de) 1996-01-15

Family

ID=21798698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88903026T ATE132195T1 (de) 1987-03-02 1988-02-29 Rekombinant-mykobakterielle impfstoffe

Country Status (6)

Country Link
EP (2) EP0347425B1 (de)
JP (2) JP3011939B2 (de)
AT (1) ATE132195T1 (de)
CA (1) CA1336270C (de)
DE (1) DE3854840D1 (de)
WO (1) WO1988006626A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807723A (en) * 1987-03-02 1998-09-15 Whitehead Institute For Biomedical Research Homologously recombinant slow growing mycobacteria and uses therefor
US5504005A (en) * 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
WO1990010701A1 (en) * 1989-03-08 1990-09-20 Commonwealth Scientific And Industrial Research Organisation Expression system for actinomycetes and related organisms
DE69027956T2 (de) * 1989-05-31 1997-03-06 Ajinomoto Kk Sekretorische Expressionsvektoren für Mycobakterien sowie Transformanten
JP2903414B2 (ja) * 1989-05-31 1999-06-07 味の素株式会社 抗酸菌分泌発現ベクター及び抗酸菌
DE69034100T2 (de) * 1989-06-19 2004-06-09 Whitehead Institute For Biomedical Research, Cambridge Verktorvermittelte genominsertion und expression von dna in bcg
WO1991013157A1 (en) * 1990-02-26 1991-09-05 Commonwealth Scientific And Industrial Research Organisation Shuttle plasmid for escherichia coli and mycobacteria
CA2045842A1 (en) * 1990-07-16 1992-01-17 William R. Jacobs Dna capable of site-specific integration into mycobacteria
WO1992021376A1 (en) * 1991-06-06 1992-12-10 Med Immune, Inc. Induction of ctl responses to foreign antigens expressed in mycobacteria
EP0587765A4 (de) * 1991-06-06 1994-11-02 Medimmune Inc Induktion der immunantwort gegen das tetanustoxin durch verarbeitung von mycobakterien, die das tetanustoxin oder fragmente davon exprimieren.
US6566121B1 (en) 1991-06-13 2003-05-20 Albert Einstein College Of Medicine Of Yeshiva University Insertional mutations in mycobacteria
CA2111217A1 (en) * 1991-06-13 1992-12-23 Albert Einstein College Of Medicine, A Division Of Yehiva University Insertional mutations in mycobacteria
JPH07502646A (ja) * 1991-10-21 1995-03-23 メディミューン，インコーポレーテッド リポタンパク質の分泌シグナルをコード化するｄｎａを含む細菌発現ベクター
CN1055701C (zh) * 1993-10-19 2000-08-23 味之素株式会社 能诱导对hiv免疫应答的肽及含有该肽的预防、治疗aids的药物
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
ES2313719T3 (es) 1993-11-23 2009-03-01 The Regents Of The University Of California Productos extracelulares abundantes y procedimiento de produccion y uso de los mismos.
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
US6221364B1 (en) * 1996-11-12 2001-04-24 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacteria auxotrophic for diaminopimelate
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US5972700A (en) * 1997-09-26 1999-10-26 Albert Einstein College Of Medicine Of Yeshiva University TM4 conditional shuttle phasmids and uses thereof
KR100503438B1 (ko) * 1998-06-12 2005-09-26 에스케이케미칼주식회사 테레프탈산의 제조방법
US6693087B1 (en) 1998-08-20 2004-02-17 Aventis Pasteur Limited Nucleic acid molecules encoding POMP91A protein of Chlamydia
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
EP1105490A1 (de) 1998-08-20 2001-06-13 Aventis Pasteur Limited Einschlussmembranprotein c von chlamydia kodierende nukleinsäuremoleküle
US6291190B1 (en) * 1998-08-25 2001-09-18 The Board Of Trustees Of The Leland Stanford Junior University Molecular differences between species of the M. tuberculosis complex
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
US6924118B2 (en) * 2000-04-17 2005-08-02 The Regents Of The University Of California Recombinant intracellular pathogen immunogenic compositions and methods for use
US6471967B1 (en) * 2000-04-17 2002-10-29 The Regents Of The University Of California Recombinant intracellular pathogen vaccines and methods for use
EP1792995A3 (de) 2000-05-08 2007-06-13 Sanofi Pasteur Limited Chlamydia Antigene, entsprechende DNS Fragmente und ihre Verwendungen
WO2001085932A2 (en) 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
US7364739B2 (en) 2000-08-25 2008-04-29 National Research Council Of Canada Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections
EP1343894A4 (de) 2000-11-02 2005-05-04 Univ Singapore Aopb-gen, -protein, homologe, fragmente und varianten davon und ihre verwendung bei der zelloberflächenpräsentation
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
JP2005529622A (ja) 2002-06-19 2005-10-06 ヴェーイーベー・ヴェーゼットウェー 腸吸収を促進するための方法および手段
EP1684798A4 (de) 2003-10-16 2007-12-05 Univ California Rekombinante intrazelluläre pathogen-immunogene zusammensetzungen und anwendungsverfahren
US8383132B2 (en) 2003-10-16 2013-02-26 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
DK2119450T3 (da) 2005-11-29 2013-05-06 Actogenix Nv Induktion af mucosal tolerance over for pankreatisk ø-beta-celle-autoantigener
ES2492468T3 (es) 2007-01-25 2014-09-09 Actogenix N.V. Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado
KR101741426B1 (ko) 2008-12-24 2017-05-30 더 킹덤 오드 더 네덜란드, 레프리젠티드 바이 더 미니스트리 오브 헬스, 웰페어 앤드 스포츠, 온 비하프 오브 더 미니스터, 더 내셔널 인스티튜트 포 퍼블릭 헬스 앤드 디 인바이런먼트 변형된 스트렙토코커스 뉴모니아 뉴몰리신(ｐｌｙ) 폴리펩타이드
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
US9717781B2 (en) 2011-08-08 2017-08-01 Alexander Shneider Methods and compositions relating to P62 for the treatment and prophylaxis of cancer
CA2884918C (en) 2012-09-17 2019-01-08 Novartis Tiergesundheit Ag Salmonid alphavirus and uses thereof
ES2642879T3 (es) 2012-11-02 2017-11-20 Novartis Tiergesundheit Ag Flavivirus asociados a la enfermedad de Theiler
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
SG11201605316VA (en) 2013-12-29 2016-07-28 Curelab Oncology Inc Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases
WO2016020856A2 (en) 2014-08-05 2016-02-11 MabQuest SA Immunological reagents
CN108779168A (zh) 2015-12-05 2018-11-09 沃迪奥斯大学医院中心 Hiv结合剂
EP3964529A1 (de) 2016-01-22 2022-03-09 Mabquest SA Nicht-blockierende pd1 spezifische antikörper
KR102217613B1 (ko) * 2019-05-23 2021-02-18 이석무 데크 난간대
US20220267416A1 (en) 2019-07-15 2022-08-25 Lausanne University Hospital Hiv binding agents
TW202206098A (zh) 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
WO2023034804A1 (en) 2021-08-31 2023-03-09 Zoetis Services Llc Attenuated alphavirus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000787A (en) 1910-10-06 1911-08-15 Otto H Davidter Wagon-rack standard.
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
JPH0734745B2 (ja) * 1984-10-05 1995-04-19 味の素株式会社 形質導入方法
EP0176321B1 (de) * 1984-09-27 1989-08-23 Eli Lilly And Company Rekombinante DNA-Cosmid-Shuttlevektoren

Also Published As

Publication number Publication date
CA1336270C (en) 1995-07-11
DE3854840D1 (de) 1996-02-08
JPH02504461A (ja) 1990-12-20
WO1988006626A1 (en) 1988-09-07
JP3011939B2 (ja) 2000-02-21
EP0681026A1 (de) 1995-11-08
EP0347425B1 (de) 1995-12-27
EP0347425A1 (de) 1989-12-27
JPH11335296A (ja) 1999-12-07

Similar Documents

Publication Publication Date Title
ATE132195T1 (de) Rekombinant-mykobakterielle impfstoffe
DE68929507D1 (de) Rekombinante mykobakterielle expressions-träger sowie deren verwendung
Batteiger et al. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis
ZA883954B (en) Avirulent microbes and uses therefor
EP0841941A4 (de) Neuartige nicht pyrogene bakterienstämme und ihre verwendung
IL107025A0 (en) Recombinant multivalent m protein vaccine
NZ235260A (en) Borrelia burgdorferi antigens, monoclonal antibodies to these, pathogenic strain, dna encoding antigens, vectors and vaccines against lyme disease
EP0692031A4 (de) Heterologe antigene in stämmen zur impfung mit lebendzellen
ATE120487T1 (de) Therapeutische zusammensetzungen gegen streptokokken-infektionen, transformierte wirte, verfahren zur immunisierung und gentechnologisch hergestellte produkte.
ATE250133T1 (de) Verktorvermittelte genominsertion und expression von dna in bcg
IL100010A0 (en) Avirulent strain of salmonella typhi,its preparation and vaccines containing it
EP0294469A4 (de) Impfstoffe und diagnosetest für haemophilus influenzae.
MY105080A (en) Heat-labile toxin b subunit fusion proteins.
ATE73349T1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
FR2636842B1 (fr) Proteine de fusion d'une sequence derivee de la sous-unite b de la toxine cholerique et d'un antigene heterologue doue de proprietes immunogenes, compositions de vaccins les contenant et acides nucleiques recombinants contenant une sequence de nucleotides codant pour ladite proteine de fusion
AU3379693A (en) Vaccines and diagnostic assays for haemophilus influenzae
AU4334193A (en) Infectious bovine rhinotracheitis virus mutants and vaccines
Bloom et al. Development of recombinant BCG vaccines.
ES2074965A1 (es) Virus mutante recombinante de rinotraqueitis infecciosa bovina y vacunas que lo contienen.
Ventures Immunization against Entamoeba histolytica-associated amebi-asis; using 170kDa purified galactose-specific lectin of E.
CA2025938A1 (en) Cloning of the gene which codes for the pilinic subunit fim3 of bordetella pertussis
ES2088371A1 (es) Procedimiento para la produccion en forma recombinante de antigenos de la glicoproteina ge de herpesvirus bovino tipo 1 y su uso en la diferenciacion serologica entre animales infectados y animales vacunados.